Growth & profitability
- Revenue has declined 29.6% per year over the past 5 years.
Financial health
- The company is unprofitable; at its current free-cash-flow burn it has roughly 3.3 years of cash runway.
IMNM Financials Immunome Inc.
7 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $7M | -$212M | 0.0% | -3228.8% | -$201M | — | $653M |
| 2024 | $9M | -$293M | 0.0% | -3382.4% | -$118M | — | $143M |
| 2023 | $14M | -$107M | 0.0% | -781.4% | -$8M | — | $99M |
| 2022 | — | -$37M | — | — | -$29M | — | $20M |
| 2021 | — | -$25M | — | — | -$18M | — | $49M |
| 2020 | — | -$18M | — | — | -$13M | $500000 | $40M |
| 2019 | — | -$10M | — | — | -$10M | — | $3M |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $0 | -$54M | — | — | -$62M | — | $583M |
| Dec '25 | $0 | -$70M | — | — | -$52M | — | $653M |
| Sep '25 | $0 | -$57M | — | — | -$42M | — | $273M |
| Jun '25 | $4M | -$43M | 0.0% | -1157.6% | -$50M | — | $144M |
| Mar '25 | $3M | -$42M | 0.0% | -1525.5% | -$57M | — | $258M |
| Dec '24 | $3M | -$80M | 0.0% | -3030.3% | -$43M | — | $143M |
| Sep '24 | $3M | -$47M | 0.0% | -1736.2% | -$36M | — | $156M |
| Jun '24 | $2M | -$36M | 0.0% | -1692.4% | -$26M | — | $165M |
| Mar '24 | $1M | -$129M | 0.0% | -12857.0% | -$13M | — | $270M |
| Dec '23 | $4M | -$93M | 0.0% | -2473.9% | -$18M | — | $99M |
| Sep '23 | $4M | -$4M | 0.0% | -130.0% | -$9M | — | $91M |
| Jun '23 | $4M | -$6M | 0.0% | -135.4% | -$6M | — | $38M |
| Mar '23 | $2M | -$4M | 0.0% | -189.1% | $24M | — | $44M |
| Dec '22 | — | -$8M | — | — | -$7M | — | $20M |
| Sep '22 | — | -$9M | — | — | -$8M | — | $27M |
| Jun '22 | — | -$9M | — | — | -$8M | — | $35M |
| Mar '22 | — | -$12M | — | — | -$6M | — | $43M |
| Dec '21 | — | -$8M | — | — | -$7M | — | $49M |
| Sep '21 | — | -$8M | — | — | -$4M | — | $56M |
| Jun '21 | — | -$5M | — | — | -$4M | — | $60M |
Valuation over time
How the market has priced IMNM against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has risen from 133.9× (Jan '24) to 316.4× (Jun '26).
P/S
Frequently asked questions
Is IMNM growing its revenue and profit?
Over the past 5 years, Immunome Inc.'s revenue has declined 29.6% per year. These are computed facts, not advice.
How much debt does IMNM have?
As of FY2025, Immunome Inc. reported — of total debt against $653M of cash.
What is IMNM's profit margin?
In FY2025, gross margin was —, operating margin -3228.8%, and net margin -3060.0%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.